Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry
暂无分享,去创建一个
M. Pepels | V. Tjan-Heijnen | F. Erdkamp | N. Peters | J. Tol | S. Geurts | I. Vriens | J. Heijns | M. Dercksen | B. Vriens | K. Aaldering | Linda van de Winkel | M. Meegdes | K. Ibragimova | Nathalie J A Teeuwen-Dedroog
[1] S. Chandarlapaty,et al. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Loi,et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] M. Pepels,et al. Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry , 2021, Breast Cancer Research and Treatment.
[4] J. Collins,et al. Abstract PS7-82: A real-world evidence study of treatment patterns among patients with HER2-positive metastatic breast cancer , 2021 .
[5] B. Kiely,et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) , 2020, Annals of Oncology.
[6] Sung-Bae Kim,et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. , 2020, The Lancet. Oncology.
[7] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. , 2020, The Lancet. Oncology.
[8] R. Greil,et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. , 2019, The New England journal of medicine.
[9] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.
[10] B. Hobbs,et al. Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis , 2019, Scientific Reports.
[11] H. Rugo,et al. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs , 2019, Clinical Cancer Research.
[12] P. Hall,et al. Real-world treatment in patients with HER2+ metastatic breast cancer , 2017, Breast Cancer Research and Treatment.
[13] W. Gradishar,et al. NCCN Guidelines Updates: Breast Cancer. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[14] I. Desideri,et al. Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. , 2016, Cancer treatment reviews.
[15] Wei Li,et al. Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study , 2015, OncoTargets and therapy.
[16] G. Fasola,et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. , 2014, The oncologist.
[17] Sung-Bae Kim,et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. , 2013, European journal of cancer.
[18] R. Schiff,et al. Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications , 2013, Breast Care.
[19] H. Rugo,et al. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. , 2013, The oncologist.
[20] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[21] J. Niland,et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study , 2012, Breast Cancer Research.
[22] J. Baselga,et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Loibl,et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Gottfried Konecny,et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.
[25] Ennis,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.